Oxford Biomedica

Oxford Biomedica is a UK-based company with a leading position in cancer immunotherapy and gene-based products. It is focusing its efforts on two clinical programmes, ProSavin and TroVax, and has an ocular collaboration with Sanofi-Aventis.

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

Actinogen Medical – equity proposition

Uncovering Trusts – Patria Private Equity Trust (PPET) – A gateway to top European private equity managers

Greggs – executive interview

About Edison

About Edison

Careers

Oxford Biomedica (LSE: OXB)

Latest Insights

Oxford Biomedica — COVID vaccine and Kymriah news encouraging

Oxford Biomedica: Edison Open House Healthcare 2022

Oxford Biomedica — Driving innovation in a thriving CGT industry

Oxford Biomedica – executive interview

Sector

Oxford Biomedica — Investing for future growth

Oxford Biomedica — Burgeoning bioprocessing revenues

Oxford BioMedica — Santen – a global player in ophthalmology

Oxford Biomedica — In a cell and gene therapy sweet spot

Oxford BioMedica — Diversified strategy showing its strength

Oxford BioMedica — Golden age for LentiVector as Axovant signs deal

Oxford BioMedica — Validation achieved, growth expected

Oxford BioMedica — LentiVector platform expanding into haemophilia

Oxford BioMedica — CTL019 approval likely in pALL, ad-com positive

Oxford BioMedica — Lentiviral vector supply for CTL019 driving revenue growth

Oxford BioMedica — CTL019 and product out-licensing to drive 2017

Oxford BioMedica — Update 5 December 2016

Oxford BioMedica — Update 2 December 2016

Oxford BioMedica — Update 24 October 2016